Paid Clinical Trials Reno

Discover 176 paid clinical trials in Reno, Nevada. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 176

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Reno NV, Truckee CA, Carson City NV, Auburn CAshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Reno NV, Truckee CA, Carson City NV, Cameron Park CAshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Reno NV, Carson City NV, Martinez CA, Walnut Creek CAshow 368 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography Test

VilobelimabJUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Recruiting

PHASE2

Sponsor:

PPD DEVELOPMENT, LP

Location:

Reno NV, Boise ID

Code:

NCT06701682

Conditions

Acute Respiratory Distress Syndrome (ARDS)

ARDS

ARDS (Acute Respiratory Distress Syndrome)

Acute Respiratory Distress Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cohort A: vilobelimab

Cohort A: placebo

NSI-8226A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis

Recruiting

PHASE2

Sponsor:

Uniquity One (UNI)

Location:

Reno NV, Sandy UT, Ogden UT, San Diego CAshow 6 more

Code:

NCT06598462

Conditions

Eosinophilic Esophagitis (EoE)

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Solrikitug Low Dose

Solrikitug Mid Dose

Solrikitug High Dose

Placebo

Zongertinib vs. Standard TreatmentBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting

PHASE3

Sponsor:

Boehringer Ingelheim

Location:

Reno NV, Fresno CA, Glendale CA, Beverly Hills CAshow 17 more

Code:

NCT06151574

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

zongertinib

pembrolizumab

cisplatin

carboplatin

pemetrexed

SelinexorSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Recruiting

PHASE3

Sponsor:

Karyopharm Therapeutics Inc

Location:

Reno NV, San Francisco CA, Palo Alto CA, Las Vegas NVshow 71 more

Code:

NCT05611931

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selinexor

Matching Placebo for selinexor

Sacituzumab vs. TreatmentA Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Reno NV, Eugene OR, Los Angeles CA, Newport Beach CAshow 32 more

Code:

NCT06459180

Conditions

Cervical Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Tirumotecan

Pemetrexed

Tisotumab Vedotin

Topotecan

Vinorelbine

Golcadomide & R-CHOPStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Recruiting

PHASE3

Sponsor:

Celgene

Location:

Reno NV, San Francisco CA, Portland OR, Tacoma WAshow 42 more

Code:

NCT06356129

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Golcadomide

Placebo

Rituximab

Cyclophosphamide

Doxorubicin

AvacopanA Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting

Sponsor:

Amgen

Location:

Reno NV, Fremont CA, Fresno CA, Covina CAshow 33 more

Code:

NCT06072482

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Avacopan

Placebo

Standard of Care